Purespring Positive About Prospects Despite Burst Biotech Bubble
UK Gene Therapy Moving Quickly Towards Clinic
Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.
